title: Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.
abstract: Anagliptin is a novel dipeptidyl peptidase-4 inhibitor that has been available in Japan since 2012. Because anagliptin is not generally used in countries other than Japan, there are only a small number of reports investigating the effects of anagliptin. In the present article, we review the safety and efficacy of anagliptin according to data obtained from preclinical trials and postmarketing studies. The usual dose of anagliptin is 200 mg daily, and increases in the dose up to 400 mg daily have been approved in cases in which the blood glucose-lowering effect is insufficient. In a Phase II trial, the reduction in the HbA1c values from baseline after 12 weeks monotherapy with 200 mg and 400 mg of daily anagliptin was 0.75%±0.50% and 0.82%±0.46%, respectively, and more than 40% of the subjects receiving anagliptin at a dose of 200 mg or 400 mg daily achieved an HbA1c level below 6.9%. Furthermore, the levels of HbA1c, fasting blood glucose, and postprandial blood glucose were significantly decreased at 52 weeks compared with the baseline values in a Phase III trial investigating the effects of anagliptin included in combination therapy with other oral antidiabetic agents. In a pooled analysis of Phase II and Phase II/III trials, the goal achievement rates for an HbA1c level below 7.0% at 12 weeks were 40.3%, 39.4%, 30.0%, and 34.8% in the patients treated with anagliptin combined with α-glucosidase inhibitors, thiazolidinediones, sulfonylureas, and biguanides, respectively. Meanwhile, the serum lipid concentrations significantly improved after the administration of anagliptin in a pooled analysis of Phase III trials, and no serious adverse effects have been reported in preclinical trials. Therefore, the use of anagliptin in patients with type 2 diabetes is considered to be safe and effective for both monotherapy and combination therapy.
authors.affiliation: Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital Higashikoiwa, Edogawa-ku, Tokyo, Japan.
authors.forename: Shinya
authors.initials: S
authors.lastname: Nishio
authors.affiliation: Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital Higashikoiwa, Edogawa-ku, Tokyo, Japan.
authors.forename: Mariko
authors.initials: M
authors.lastname: Abe
authors.affiliation: Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital Higashikoiwa, Edogawa-ku, Tokyo, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ito
keywords: adverse effect; combination therapy; dipeptidyl peptidase-4 inhibitor; monotherapy; type 2 diabetes mellitus
references.citation: N Engl J Med. 2013 Oct 3;369(14):1317-26
references.pmid: 23992601
references.citation: Int J Cardiol. 2013 Oct 3;168(3):e106
references.pmid: 23972359
references.citation: Biosci Biotechnol Biochem. 2013;77(11):2305-8
references.pmid: 24200798
references.citation: Nephrol Dial Transplant. 2010 Apr;25(4):1161-7
references.pmid: 19892756
references.citation: Endocrinology. 2013 Mar;154(3):1260-70
references.pmid: 23337530
references.citation: Diabetes Obes Metab. 2011 Mar;13(3):258-67
references.pmid: 21205122
references.citation: Diabetes Care. 2014 Jan;37 Suppl 1:S14-80
references.pmid: 24357209
references.citation: Diabetes Res Clin Pract. 2007 Apr;76(1):132-8
references.pmid: 17223217
references.citation: Diabetes Obes Metab. 2013 Feb;15(2):112-20
references.pmid: 22925682
references.citation: Am J Kidney Dis. 2012 Nov;60(5):850-86
references.pmid: 23067652
references.citation: Diabetes Obes Metab. 2013 Jul;15(7):668-73
references.pmid: 23489301
references.citation: Diabetes Care. 2008 Dec;31(12):2315-7
references.pmid: 18809631
references.citation: Scand J Gastroenterol. 1995 Sep;30(9):892-6
references.pmid: 8578189
references.citation: Diabetes Care. 2001 Mar;24(3):489-94
references.pmid: 11289473
references.citation: Diabetes Care. 2006 Dec;29(12):2632-7
references.pmid: 17130196
references.citation: Cardiovasc Ther. 2014 Aug;32(4):147-58
references.pmid: 24750644
references.citation: N Engl J Med. 2013 Oct 3;369(14):1327-35
references.pmid: 23992602
references.citation: Diabet Med. 2005 May;22(5):654-7
references.pmid: 15842525
references.citation: Diabetes Obes Metab. 2013 Sep;15(9):810-8
references.pmid: 23464664
references.citation: Diabetes Obes Metab. 2007 Sep;9(5):733-45
references.pmid: 17593236
references.citation: Hypertension. 2009 Sep;54(3):516-23
references.pmid: 19581505
references.citation: Int Heart J. 2013;54(2):93-7
references.pmid: 23676369
references.citation: Diabetes Care. 2014 Oct;37(10):2864-83
references.pmid: 25249672
references.citation: J Diabetes Complications. 2012 Jul-Aug;26(4):286-90
references.pmid: 22621778
references.citation: J Clin Endocrinol Metab. 2011 Nov;96(11):3448-56
references.pmid: 21865372
references.citation: Scand J Gastroenterol. 2013 Oct;48(10):1152-9
references.pmid: 24047394
references.citation: Curr Med Res Opin. 2009 Oct;25(10):2401-11
references.pmid: 19650754
references.citation: Endocrine. 2015 Apr;48(3):1005-9
references.pmid: 25115636
references.citation: Nutr Metab (Lond). 2010 Nov 12;7:83
references.pmid: 21070671
references.citation: Diabetes Ther. 2013 Dec;4(2):321-9
references.pmid: 23801219
references.citation: Expert Opin Pharmacother. 2015 Feb;16(3):289-96
references.pmid: 25529857
references.citation: Diabetes Care. 2014 Apr;37(4):985-92
references.pmid: 24198301